CD85d
Showing 26 - 50 of >10,000
Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive Trial in Houston (Acalabrutinib, Venetoclax)
Recruiting
- Blastoid Variant Mantle Cell Lymphoma
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma Trial in United States (procedure, drug,
Recruiting
- HIV Infection
- +10 more
- Autologous Hematopoietic Stem Cell Transplantation
- +7 more
-
La Jolla, California
- +3 more
Dec 7, 2022
CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma Trial in Houston (Brentuximab Vedotin, Laboratory Biomarker
Recruiting
- CD30-Positive Neoplastic Cells Present
- Malignant Mesothelioma
- Brentuximab Vedotin
- Laboratory Biomarker Analysis
-
Houston, TexasM D Anderson Cancer Center
Jan 3, 2022
Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,
Completed
- Grade 3a Follicular Lymphoma
- +9 more
- Laboratory Biomarker Analysis
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 31, 2023
Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma Trial in
Recruiting
- Recurrent Anaplastic Large Cell Lymphoma
- +9 more
- Anti-CD30/CD16A Monoclonal Antibody AFM13
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2022
Healthy, Cytotoxicity, Yellow Fever Vaccination Reaction Trial in Aarhus (Yellow Fever Vaccine)
Unknown status
- Healthy
- +2 more
- Yellow Fever Vaccine
-
Aarhus, DenmarkAarhus University Hospital
Oct 28, 2021
Metastatic Malignant Tumor in the Liver, Metastatic Uveal Melanoma Trial in Houston (Aldesleukin, Autologous CD8+
Active, not recruiting
- Metastatic Malignant Neoplasm in the Liver
- Metastatic Uveal Melanoma
- Aldesleukin
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jan 20, 2023
Perianal Abscess, Anal Fistulas, Incontinence Trial in Umea (Perianal abscess drainage, 3D ultrasonography)
Recruiting
- Perianal Abscess
- +2 more
- Perianal abscess drainage
- 3D ultrasonography
-
Umea, County Of Vasterbotten §, SwedenDepartment of Surgery
May 17, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Acalabrutinib, Obinutuzumab)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib
- Obinutuzumab
-
Houston, TexasM D Anderson Cancer Center
Jul 14, 2022
Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive, Philadelphia Chromosome Positive Trial in Monrovia,
Recruiting
- Blasts 5 Percent or More of Bone Marrow Nucleated Cells
- +4 more
- ADCT-602
-
Monrovia, California
- +1 more
Dec 7, 2022
Cutaneous Melanoma, Pleural Mesothelioma, HER2 Negative Breast Tumors Trial in Worldwide (SGN-CD228A)
Active, not recruiting
- Cutaneous Melanoma
- +5 more
-
Birmingham, Alabama
- +13 more
Jan 23, 2023
Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia, Early Relapse of Acute Myeloid Leukemia Trial in Duarte
Active, not recruiting
- Adult Acute Myeloid Leukemia in Remission
- +12 more
- cyclophosphamide
- +4 more
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 17, 2022
Nodular Lymphocyte Predominant Hodgkin Lymphoma, Recurrent Nodular Lymphocyte Predominant Hodgkin Lymphoma, Refractory Nodular
Not yet recruiting
- Nodular Lymphocyte Predominant Hodgkin Lymphoma
- +2 more
- Biopsy
- +9 more
- (no location specified)
Jun 1, 2023
Celiac Disease Trial in Palo Alto (Latiglutenase, Placebo)
Recruiting
- Celiac Disease
- Latiglutenase
- Placebo
-
Palo Alto, CaliforniaStanford University
Aug 2, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Cyclophosphamide, Fludarabine Phosphate, Ibrutinib)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Cyclophosphamide
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
B-cell Acute Lymphoblastic Leukemia Trial in France, United States (UCART22)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- UCART22
- CLLS52
-
Los Angeles, California
- +10 more
Sep 23, 2022
Multiple Myeloma Trial in Shanghai (GC012F injection)
Recruiting
- Multiple Myeloma
- GC012F injection
-
Shanghai, Shanghai, ChinaShanghai Changzheng Hospital
Jul 23, 2022
Non-Malignant Tumor Trial in Seattle (biological, drug, radiation, procedure)
Recruiting
- Non-Malignant Neoplasm
- Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
- +7 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 29, 2022
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Duarte (Basiliximab, Carmustine, Cytarabine)
Recruiting
- Recurrent Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- Basiliximab
- +6 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jun 16, 2022
Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia Trial in
Terminated
- Philadelphia Chromosome Negative
- +2 more
- Blinatumomab
- +11 more
-
Houston, TexasM D Anderson Cancer Center
Nov 3, 2022
Recurrent Plasma Cell Myeloma Trial in Houston (Daratumumab)
Recruiting
- Recurrent Plasma Cell Myeloma
- Daratumumab
-
Houston, TexasM D Anderson Cancer Center
Dec 22, 2021
Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in
Not yet recruiting
- Ovarian Clear Cell Adenocarcinoma
- +14 more
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140
- +4 more
-
Buffalo, New York
- +1 more
Dec 16, 2022
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in
Recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +3 more
- Acalabrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 17, 2022